证券代码：603387 证券简称：基蛋生物 公告编号：2025-026 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本案件二审已立案审查，尚未开庭， 也未产生有效判决，暂时无法判断对公司本期利润和期后利润的影响。公司将根 据诉讼进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风 险。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"基蛋生物"或"公司"）于 2020 年完成对武汉景川诊断技术股份有限公司（以下简称"景川诊断"）的收购，成 为其控股股东。公司作为收购人就避免与景川诊断（含其子公司）构成同业竞争， 在《收购报告书》中承诺自承诺函出具日起，以及作为景川诊断的第一大股东期 间，将不在中国境内外直接或间接从事或参与任何与景川诊断现有主营业务相竞 争的业务及活动，或拥有与景川诊断存在竞争关系的任何经济实体、机构、经济 组织的权益。 原告武汉众聚成咨询管理有限责任公司（以下简称"武汉众聚成"）认为 ...

Group 1 - The core viewpoint of the news highlights the current performance and market position of the company, Jidan Biotechnology, in the medical device industry, noting its low PE ratio compared to industry averages [1] - As of July 16, Jidan Biotechnology's closing price was 8.38 yuan, with a PE ratio of 21.05, marking a new low in 70 days, and a total market capitalization of 4.25 billion yuan [1] - The company ranks 48th in the medical device industry, which has an average PE ratio of 51.87 and a median of 37.48 [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - As of the Q1 2025 report, four institutions held shares in Jidan Biotechnology, totaling 28.14 million shares with a market value of 236 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Jidan Biotechnology, which closed at 8.19 yuan with a rolling PE ratio of 20.57, marking a new low in 21 days, and a total market capitalization of 4.154 billion yuan [1] - The average PE ratio for the medical device industry is 51.40, with a median of 37.27, positioning Jidan Biotechnology at the 48th rank within the industry [1] - As of March 31, 2025, Jidan Biotechnology had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the domestic in vitro diagnostic field, especially in the POCT sector [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - The PE ratios of other companies in the industry range from 10.28 to 20.57, with Jidan Biotechnology's PE ratio being lower than the industry average and median [2]

Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-025 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本案件二审已立案审查，尚未开庭， 也未产生有效判决，暂时无法判断对公司本期利润和期后利润的影响。公司将根 据诉讼进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风 险。 议、会计凭证、会计账簿、财务报表、审计报告及财务会计报告（包括资产负债 表、利润表、现金流量表、资产减值准备明细表、利润分配表、股东权益增减变 动表、其他有关附表）等材料交由基蛋生物查阅和复制； 2、判令基蛋生物有权委托会计师、律师等中介机构执业人员辅助进行上述 查阅和复制事宜； 3、判令本案全部诉讼费由景川诊断承担。 具体内容详见公司于 2024 年 12 月 25 日披露的《基蛋生物：关于公司涉及 诉讼的公告》（公告编号：2024-049）。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"公司"或"基蛋生物"）作 ...

Key Points - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets on July 4, providing insights for investors [2] Group 1: Major Corporate Actions - China Shipbuilding Industry Corporation's absorption and merger with China Shipbuilding Industry Group has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Aerospace Hongtu's controlling shareholder's action party plans to transfer 5.1% of the company's shares to a private equity fund at a price of 19 yuan per share, totaling 253 million yuan [4] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, with the transaction price yet to be determined [5] - Haitai Development intends to transfer 100% of its subsidiary's equity for 90.6595 million yuan, aiming to optimize its asset structure [6] - Gensun Bio plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [7] - Xinhua Insurance intends to invest 11.25 billion yuan to subscribe to a private equity fund, which has a total size of 22.5 billion yuan [8] - Huaming Equipment has raised its share repurchase fund limit from 200 million yuan to 250 million yuan [9] - Aotewei's controlling shareholders plan to transfer 4.99% of the company's shares through a pricing inquiry [10] - Jianke Institute plans to publicly transfer 40% of its stake in Hubei Jiansheng Engineering Technology Consulting Co., Ltd. [11] - Aerospace Electronics plans to increase capital in its subsidiary to enhance its capabilities in unmanned systems [12] Group 2: Financial Performance - Jin Xin Nong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [14] - Tianbang Food's June pig sales revenue decreased by 4.01% month-on-month, with a total of 4.143 billion yuan for the first half of 2025 [15] - GAC Group's June automobile sales fell by 8.22% year-on-year, with a total of 755,300 vehicles sold in the first half of 2025, down 12.48% [16] - Pulite expects a net profit increase of 38.88% to 66.65% for the first half of 2025, driven by growth in modified materials and new energy businesses [18] - Zhuye Group anticipates a net profit increase of 50.97% to 75.23% for the first half of 2025, benefiting from rising precious metal prices [19] - Xindong Lian Ke expects a net profit increase of 144.46% to 199.37% for the first half of 2025, supported by sufficient orders and revenue growth [20] - Zhongce Rubber forecasts a net profit decrease of 6.3% to 11.81% for the first half of 2025, due to a one-time gain in the previous year [21] - *ST Sihua expects a net loss of 11 million to 17 million yuan for the first half of 2025, despite significant sales order growth [22] - Sankeshu anticipates a net profit increase of 80.94% to 119.04% for the first half of 2025, driven by growth in retail business and improved gross margins [23] Group 3: Major Contracts and Shareholding Changes - Hongsheng Huayuan's subsidiary is expected to win a bid for a project worth approximately 1.127 billion yuan from the Southern Power Grid [25] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [26] - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [27] - Yue Wanniang's controlling shareholder plans to reduce its stake by up to 6% through various trading methods [28] - Maipu Medical's shareholder plans to reduce its stake by up to 665,100 shares, representing 0.9999% of the total shares [29] - Jiulian Technology's directors and senior management plan to reduce their holdings by up to 2.61% of the total shares [30] - *ST Huawang's shareholder plans to reduce its stake by up to 1.76% through trading methods [32]

Financial Performance - Whirlpool expects a net profit of approximately 205 million yuan for the first half of 2025, an increase of about 174 million yuan or approximately 559% year-on-year [2] - Chipmotion Technology anticipates a net profit between 138 million to 169 million yuan for the first half of 2025, representing a year-on-year growth of approximately 144.46% to 199.37% [2] Mergers and Acquisitions - China Shipbuilding's absorption merger with China Shipbuilding Industry Corporation has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, which constitutes a major asset restructuring [4] Shareholder Actions - Aotewei's actual controllers plan to transfer 4.99% of the company's shares, totaling 15.75 million shares, due to personal funding needs [5] - Yaguang Technology's chairman has been placed under detention, but the company's operations remain normal [5] Industry Developments - Ningbo Port expects a 9.8% year-on-year increase in container throughput for the first half of 2025 [8] - Three Trees anticipates a net profit growth of 80.94% to 119.04% for the first half of 2025 [8] - Zhuhai Group expects a net profit increase of 50.97% to 75.23% for the first half of 2025 [8] Project Wins - Sanxing Medical's subsidiary has pre-qualified for a 306 million yuan project with Southern Power Grid [8] - Hopu Co., Ltd. has jointly won a 449 million yuan shared energy storage demonstration project [8] - Hongsheng Huayuan's subsidiary has pre-qualified for an 1.127 billion yuan project with Southern Power Grid [8]

Corporate Announcements - Aerospace Hongtu's controlling shareholder plans to transfer 5.1% of the company's shares, totaling 13.33 million shares at a price of 19 yuan per share, amounting to 253 million yuan [3] - Haitai Development intends to transfer 100% equity of its subsidiary for 90.66 million yuan, which is part of its strategic transformation to optimize asset structure [4] - G-Biosciences plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [5] - New China Life Insurance intends to invest 11.25 billion yuan to subscribe to a private fund, which has a total scale of 22.5 billion yuan [6] - Huaming Equipment has increased its share repurchase fund limit from 200 million yuan to 250 million yuan [7] Performance Updates - Jinxinnong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [9] - Tianbang Foods reported a 4.01% month-on-month decline in June sales revenue for commodity pigs, totaling 675 million yuan [10] - GAC Group's June automobile sales were 150,100 units, a year-on-year decrease of 8.22% [11] - Pulit expects a net profit of 200 million to 240 million yuan for the first half of 2025, a year-on-year increase of 38.88% to 66.65% [12] - Zhuyue Group anticipates a net profit of 560 million to 650 million yuan for the first half of 2025, a year-on-year increase of 50.97% to 75.23% [14] - Xindong Lianke expects a net profit of 138 million to 169 million yuan for the first half of 2025, a year-on-year increase of 144.46% to 199.37% [15] - Zhongce Rubber expects a net profit of 2.24 billion to 2.38 billion yuan for the first half of 2025, a year-on-year decrease of 6.3% to 11.81% [16] - ST Sitong anticipates a net loss of 11 million to 17 million yuan for the first half of 2025, compared to a loss of 9.08 million yuan in the same period last year [17] Major Contracts - Hongsheng Huayuan's subsidiary is expected to win a bid for a Southern Power Grid project worth approximately 1.127 billion yuan, accounting for 11.12% of the company's 2024 revenue [19] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [20] Shareholding Changes - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [22]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-024 基蛋生物科技股份有限公司 本次投资不构成关联交易，也不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 二、审议情况 2025 年 7 月 4 日，公司召开第四届董事会第六次会议及第四届监事会第六 次会议，审议通过了《关于投资建设智能化生产研发基地的议案》，同意公司使 用自有资金投资建设智能化生产研发基地。上述议案无需经公司股东大会审议。 三、投资项目的基本情况 关于投资建设智能化生产研发基地的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资项目名称：智能化生产研发基地 投资金额：预计总投资约 1.5 亿元人民币，包含土地价款、建筑主体工 程及配套设施工程费用。项目最终投资总额以实际投资金额为准。 相关风险提示：在项目建设过程中，可能存在相关政策、宏观经济等方 面的不确定性风险，有可能会影响项目的正常实施。公司将根据实际情况，依法 合规推行项目进展，规避项目风险。公司将根据项目进展情况及时履行信息披露 义务，敬请广大投资 ...

Group 1 - The company plans to invest 150 million yuan to build an intelligent production and R&D base, which includes land costs, main construction, and supporting facility expenses [1] - The project will cover an area of approximately 40,010.27 square meters, with a total construction area of about 65,538.81 square meters, featuring a four-story comprehensive factory, high-standard storage center, and supporting R&D office facilities [1] - Upon completion, the project will enhance the production capacity for instruments and reagents in product lines such as chemiluminescence, biochemistry, and hematology [1] Group 2 - The company has obtained the necessary land for construction and relevant permits, with an expected completion date in 2028 [1]